# A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

> **NCT04200404** · PHASE1,PHASE2 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Advanced Refractory Solid Tumors

## Interventions

- **DRUG:** CS1001
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT04200404
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-13
- **Primary completion:** 2021-05-13
- **Final completion:** 2021-08-18
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04200404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04200404, "A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04200404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*